|
413 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
556 Trials |
|
44796 News |
|
| «12...615616617618619620621622623624625626627» |
- | lenalidomide / Generic mfg., clofarabine / Generic mfg.
New P1 trial: Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 25, 2012
P1, N=29, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- | dacarbazine / Generic mfg., dasatinib / Generic mfg.
Trial completion, Metastases: A Phase I/II Study of Dasatinib and Dacarbazine (clinicaltrials.gov) - Jun 25, 2012
P1/2, N=50, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 24, 2012
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- seliciclib (CYC202) - Cyclacel, Cedars / Sinai
Trial withdrawal, Combination therapy, Metastases: Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jun 21, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change: PALOMA-1;TRIO-18: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 21, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Withdrawn N=225 --> 177
- | bortezomib / Generic mfg., cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
P2 data: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) compared to cyclophosphamide, velcade and dexamethasone (CVD)for first relapse or primary refractory mutiple myeloma patients. (EUDRACT) - Jun 19, 2012
P2, N=300, Ongoing, Sponsor: University of Leeds
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 19, 2012
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Trial withdrawal: Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia (clinicaltrials.gov) - Jun 18, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
N=225 --> 177 Recruiting --> Withdrawn
- Enrollment change: Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia (clinicaltrials.gov) - Jun 18, 2012
P1, N=0, Withdrawn, Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting --> Withdrawn N=48 --> 0
- |||| temozolomide / Generic mfg., dasatinib / Generic mfg.
Enrollment open: Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jun 18, 2012
P2, N=217, Recruiting, Sponsor: North Central Cancer Treatment Group
N=48 --> 0 Suspended --> Recruiting
- PF-04217903 / Pfizer
Trial termination, Metastases: A Study of PF-04217903 in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 14, 2012
P1, N=16, Terminated, Sponsor: Pfizer
Suspended --> Recruiting Completed --> Terminated; See termination reason in detailed description.
- Istodax (romidepsin) / Astellas, BMS
Enrollment change, Metastases: Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 13, 2012
P1, N=15, Completed, Sponsor: Celgene Corporation
Completed --> Terminated; See termination reason in detailed description. N=12 --> 15
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 13, 2012
P2, N=29, Recruiting, Sponsor: University of Washington
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Metastases: Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 13, 2012
P1, N=14, Completed, Sponsor: Celgene Corporation
N=12 --> 15 Active, not recruiting --> Completed
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Metastases: Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 13, 2012
P1, N=15, Completed, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Combination therapy, Metastases: Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 11, 2012
P1, N=60, Recruiting, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Completed N=45 --> 60
- |||||||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: PRINCIPAL: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (clinicaltrials.gov) - Jun 7, 2012
P3, N=880, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- New P2 trial: Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia (clinicaltrials.gov) - Jun 7, 2012
P2, N=30, Active, not recruiting, Sponsor: Fundaci
- Arzerra (ofatumumab) / Novartis, Genmab
Enrollment open: A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 6, 2012
P2, N=10, Recruiting, Sponsor: GlaxoSmithKline
N=45 --> 60 Not yet recruiting --> Recruiting
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion: Safety of ON 01910.Na in Patients With Myelodysplasia (clinicaltrials.gov) - Jun 6, 2012
P1, N=14, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion: Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Jun 5, 2012
P1/2, N=68, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Neugranin (balugrastim biosimilar) / Teva
Trial completion, Head-to-Head: NEUGR-003: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (clinicaltrials.gov) - Jun 3, 2012
P3, N=381, Completed, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P3 trial: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - May 31, 2012
P3, N=330, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment change, Metastases: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (clinicaltrials.gov) - May 30, 2012
P3, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed N=390 --> 150
- |||||| Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (clinicaltrials.gov) - May 30, 2012
P3, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=390 --> 150 Not yet recruiting --> Recruiting
- nintedanib / Generic mfg.
Enrollment open: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 29, 2012
P1, N=29, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (clinicaltrials.gov) - May 29, 2012
P=N/A, N=62, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Cytovene (ganciclovir) / Roche
Trial withdrawal: A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir (clinicaltrials.gov) - May 28, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- PF-04691502 / Pfizer
Enrollment change, Metastases: A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients (clinicaltrials.gov) - May 28, 2012
P1, N=37, Completed, Sponsor: Pfizer
Terminated --> Withdrawn N=75 --> 37
- Cytovene (ganciclovir) / Roche
Enrollment change: A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir (clinicaltrials.gov) - May 28, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=75 --> 37 N=168 --> 0
- cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
New P2 trial: Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) - May 28, 2012
P2, N=7, Completed, Sponsor: Fred Hutchinson Cancer Research Center
- | PF-04691502 / Pfizer
Trial completion, Metastases: A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients (clinicaltrials.gov) - May 28, 2012
P1, N=37, Completed, Sponsor: Pfizer
N=168 --> 0 Active, not recruiting --> Completed
- ||| MK-2206 / Merck (MSD)
Trial completion: A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) (clinicaltrials.gov) - May 28, 2012
P1, N=72, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment open, HEOR: Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) (clinicaltrials.gov) - May 24, 2012
P=N/A, N=1000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | tovetumab (MEDI-575) / AstraZeneca
Trial completion, Metastases: A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors. (clinicaltrials.gov) - May 24, 2012
P1, N=35, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - May 23, 2012
P3, N=900, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| ipatasertib (RG7440) / Roche, Cotellic (cobimetinib) / Exelixis, Roche
Enrollment open, Combination therapy, Metastases: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 23, 2012
P1, N=108, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
New P1/2 trial, Metastases: Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor (clinicaltrials.gov) - May 20, 2012
P1/2, N=71, Recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Daurismo (glasdegib) / Pfizer
Enrollment open, Combination therapy: BRIGHT AML: A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - May 20, 2012
P1b/2, N=265, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia (clinicaltrials.gov) - May 20, 2012
P=N/A, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- alisertib (MLN8237) / Puma
New P1/2 trial, Combination therapy: Study of MLN8237 in Combination With Irinotecan and Temozolomide (clinicaltrials.gov) - May 16, 2012
P1/2, N=44, Suspended, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
- plerixafor / Generic mfg.
Trial initiation date: AMD 3100 for Treatment of Myelokathexis (clinicaltrials.gov) - May 15, 2012
P1, N=6, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Initiation date: Jul 2010 --> Oct 2010
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P1/2 trial: Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) (clinicaltrials.gov) - May 15, 2012
P1/2, N=68, Recruiting, Sponsor: JSehouli
- || dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed: Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone (clinicaltrials.gov) - May 15, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: iOMEDICO AG
Initiation date: Jul 2010 --> Oct 2010 Recruiting --> Active, not recruiting
- plerixafor / Generic mfg.
Trial completion: AMD 3100 for Treatment of Myelokathexis (clinicaltrials.gov) - May 15, 2012
P1, N=6, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) (clinicaltrials.gov) - May 14, 2012
P2, N=338, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=255 --> 338
- | Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
New P1/2 trial, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 9, 2012
P1/2, N=80, Recruiting, Sponsor: Hope Rugo, MD
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1 trial: Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer (clinicaltrials.gov) - May 9, 2012
P1, N=50, Recruiting, Sponsor: Medivation, Inc.
- PF-3758309 / Pfizer
Trial termination: This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 8, 2012
P1, N=35, Terminated, Sponsor: Pfizer
N=255 --> 338 Completed --> Terminated; See termination reason in detailed description.
- | nintedanib / Generic mfg.
New P1 trial: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 6, 2012
P1, N=29, Recruiting, Sponsor: Boehringer Ingelheim